| Authors: |
Hipp JF; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland. joerg.hipp@roche.com., Chamberlain S; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland., DiStefano C; Children's Hospital Los Angeles and University of Southern California, Department of Psychiatry, Los Angeles, California, USA., Frohlich J; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland.; fMEG Center, University of Tuebingen, Tuebingen, Germany.; Center for Autism Research and Treatment University of California, Los Angeles Semel Institute for Neuroscience, Los Angeles, USA., Hernandez MC; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland., Saravanapandian V; Center for Autism Research and Treatment University of California, Los Angeles Semel Institute for Neuroscience, Los Angeles, USA., Vogel-Farley V; Dup15q Alliance, Highland Park, Illinois, USA.; Rare Epilepsy Network, Chicago, Illinois, USA., Goeldner C; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland., Jeste SS; Children's Hospital Los Angeles and University of Southern California, Department of Psychiatry, Los Angeles, California, USA. |
